NASDAQ:TCRR - Tcr2 Therapeutics Stock Price, News, & Analysis

$16.24
+1.63 (+11.16 %)
(As of 06/19/2019 03:27 AM ET)
Today's Range
$14.30
Now: $16.24
$16.40
50-Day Range
$13.64
MA: $15.21
$18.10
52-Week Range
$13.04
Now: $16.24
$25.47
Volume15,600 shs
Average Volume40,168 shs
Market Capitalization$388.79 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. Its product candidates in pipeline comprise TC-210 mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors; TC-220 that targets MUC16 positive solid tumors; and TC-310 and TC-410 dual TRuC-T cell programs targeting CD19/22 and MSLN/MUC16, as well as TC-110 mono TRuC-T cells targeting CD19-positive B-Cell hematological malignancies. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TCRR
CUSIPN/A
CIKN/A
Phone617-949-5200

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees47
Market Cap$388.79 million
Next Earnings Date8/12/2019 (Estimated)
OptionableNot Optionable

Receive TCRR News and Ratings via Email

Sign-up to receive the latest news and ratings for TCRR and its competitors with MarketBeat's FREE daily newsletter.

Tcr2 Therapeutics (NASDAQ:TCRR) Frequently Asked Questions

What is Tcr2 Therapeutics' stock symbol?

Tcr2 Therapeutics trades on the NASDAQ under the ticker symbol "TCRR."

How were Tcr2 Therapeutics' earnings last quarter?

Tcr2 Therapeutics Inc (NASDAQ:TCRR) announced its quarterly earnings results on Monday, May, 13th. The company reported ($4.85) earnings per share for the quarter, missing analysts' consensus estimates of ($0.38) by $4.47. View Tcr2 Therapeutics' Earnings History.

When is Tcr2 Therapeutics' next earnings date?

Tcr2 Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, August 12th 2019. View Earnings Estimates for Tcr2 Therapeutics.

What price target have analysts set for TCRR?

6 Wall Street analysts have issued 12-month price objectives for Tcr2 Therapeutics' shares. Their predictions range from $16.00 to $37.00. On average, they anticipate Tcr2 Therapeutics' stock price to reach $27.80 in the next twelve months. This suggests a possible upside of 71.2% from the stock's current price. View Analyst Price Targets for Tcr2 Therapeutics.

What is the consensus analysts' recommendation for Tcr2 Therapeutics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tcr2 Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Tcr2 Therapeutics.

Has Tcr2 Therapeutics been receiving favorable news coverage?

News headlines about TCRR stock have trended very negative on Wednesday, InfoTrie Sentiment reports. The research group rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Tcr2 Therapeutics earned a media sentiment score of -3.1 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for Tcr2 Therapeutics.

Are investors shorting Tcr2 Therapeutics?

Tcr2 Therapeutics saw a increase in short interest in the month of May. As of May 31st, there was short interest totalling 152,600 shares, an increase of 50.5% from the April 30th total of 101,400 shares. Based on an average trading volume of 29,000 shares, the short-interest ratio is currently 5.3 days. Approximately 1.8% of the shares of the stock are short sold. View Tcr2 Therapeutics' Current Options Chain.

Who are some of Tcr2 Therapeutics' key competitors?

What other stocks do shareholders of Tcr2 Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tcr2 Therapeutics investors own include Novavax (NVAX), Cranswick (CWK), Cairn Energy (CNE), Clarkson (CKN), Charter Court Financial Services Grp (CCFS), Close Brothers Group (CBG), Bodycote (BOY), British American Tobacco Plc Ads (BATS), AstraZeneca (AZN) and Avast (AVST).

Who are Tcr2 Therapeutics' key executives?

Tcr2 Therapeutics' management team includes the folowing people:
  • Dr. Garry E. Menzel, Pres, CEO & Director (Age 55)
  • Mr. Robert Hofmeister, Chief Scientific Officer (Age 52)
  • Dr. Alfonso Quintas Cardama M.D., Chief Medical Officer (Age 48)
  • Mr. Mayur Amrat Somaiya, Chief Financial Officer (Age 46)

When did Tcr2 Therapeutics IPO?

(TCRR) raised $76 million in an initial public offering (IPO) on Thursday, February 14th 2019. The company issued 5,000,000 shares at a price of $14.55-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO and Wedbush PacGrow and China Renaissance were co-managers.

When does Tcr2 Therapeutics' lock-up period expire?

Tcr2 Therapeutics' lock-up period expires on Tuesday, August 13th. Tcr2 Therapeutics had issued 5,000,000 shares in its public offering on February 14th. The total size of the offering was $75,000,000 based on an initial share price of $15.00. After the expiration of Tcr2 Therapeutics' lock-up period, major shareholders and company insiders will be able to sell their shares of the company.

Who are Tcr2 Therapeutics' major shareholders?

Tcr2 Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include MPM Asset Management LLC (16.92%), MPM Asset Management LLC (16.10%), Redmile Group LLC (7.55%), Dean Capital Investments Management LLC (0.17%) and Laurion Capital Management LP (0.10%). Company insiders that own Tcr2 Therapeutics stock include Morana Jovan-Embiricos and Upnorth Investment Ltd. View Institutional Ownership Trends for Tcr2 Therapeutics.

Which major investors are buying Tcr2 Therapeutics stock?

TCRR stock was bought by a variety of institutional investors in the last quarter, including MPM Asset Management LLC, MPM Asset Management LLC, Redmile Group LLC, Dean Capital Investments Management LLC and Laurion Capital Management LP. Company insiders that have bought Tcr2 Therapeutics stock in the last two years include Morana Jovan-Embiricos and Upnorth Investment Ltd. View Insider Buying and Selling for Tcr2 Therapeutics.

How do I buy shares of Tcr2 Therapeutics?

Shares of TCRR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Tcr2 Therapeutics' stock price today?

One share of TCRR stock can currently be purchased for approximately $16.24.

How big of a company is Tcr2 Therapeutics?

Tcr2 Therapeutics has a market capitalization of $388.79 million. The company earns $-61,550,000.00 in net income (profit) each year or ($98.53) on an earnings per share basis. Tcr2 Therapeutics employs 47 workers across the globe.View Additional Information About Tcr2 Therapeutics.

What is Tcr2 Therapeutics' official website?

The official website for Tcr2 Therapeutics is http://www.tcr2.com/.

How can I contact Tcr2 Therapeutics?

Tcr2 Therapeutics' mailing address is 100 BINNEY STREET, CAMBRIDGE MA, 02142. The company can be reached via phone at 617-949-5200 or via email at [email protected]


MarketBeat Community Rating for Tcr2 Therapeutics (NASDAQ TCRR)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  22 (Vote Outperform)
Underperform Votes:  25 (Vote Underperform)
Total Votes:  47
MarketBeat's community ratings are surveys of what our community members think about Tcr2 Therapeutics and other stocks. Vote "Outperform" if you believe TCRR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TCRR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel